STOCKHOLM, July 13, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented new data at the 2026 Alzheimer's Association International Conference (AAIC), held in London, July 12-15, demonstrating that the Leqembi (lecanemab) subcutaneous...
Hence then, the article about new clinical data on the leqembi subcutaneous autoinjector presented at aaic 2026 support similar efficacy and safety to iv formulation in early alzheimer s disease was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease )
Also on site :
- 7 Brew Is Launching Its First-Ever Bakery Menu With 5 Treats for $3 Each
- Patrick Stewart’s Lifelong Favorite ‘Comfort Food’ Was a Simple British Meal He’d Been Eating Since 1948
- Todd Chrisley Reveals What He Really Thought About Savannah’s Older Fiancé Before Learning She Was Pregnant